Regeneron Pharmaceuticals (REGN) Tax Provisions (2011 - 2026)
Regeneron Pharmaceuticals' quarterly Tax Provisions came in at $104.0 million in Q1 2026, up 8.0% year-on-year from $96.3 million in Q1 2025, and down 47.76% quarter-over-quarter from $199.1 million in Q4 2025.
Regeneron Pharmaceuticals has reported Tax Provisions for 16 years, with the latest figure at $104.0 million in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions rose 8.0% year-over-year to $104.0 million; the trailing twelve-month figure through Mar 2026 stood at $733.5 million (up 51.27% YoY), and the FY2025 full-year result was $725.8 million, up 97.6% from the prior year.
- Tax Provisions for Q1 2026 stood at $104.0 million, down from $199.1 million in the prior quarter.
- The five-year high for Tax Provisions was $303.3 million in Q3 2025, with the low at -$21.3 million in Q1 2024.
- Average Tax Provisions over 5 years is $115.5 million, with a median of $111.1 million recorded in 2022.
- Year-over-year, Tax Provisions slumped 152.99% in 2024 and soared 552.11% in 2025.
- Tracing REGN's Tax Provisions over 5 years: stood at $127.6 million in 2022, then slumped by 109.4% to -$12.0 million in 2023, then surged by 436.67% to $40.4 million in 2024, then surged by 392.82% to $199.1 million in 2025, then plunged by 47.76% to $104.0 million in 2026.
- The last three Tax Provisions figures came in at $104.0 million (Q1 2026), $199.1 million (Q4 2025), and $303.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 104.00 Mn |
| Dec 31, 2025 | 199.10 Mn |
| Sep 30, 2025 | 303.30 Mn |
| Jun 30, 2025 | 127.10 Mn |
| Mar 31, 2025 | 96.30 Mn |
| Dec 31, 2024 | 40.40 Mn |
| Sep 30, 2024 | 152.40 Mn |
| Jun 30, 2024 | 195.80 Mn |
| Mar 31, 2024 | -21.30 Mn |
| Dec 31, 2023 | -12.00 Mn |
| Sep 30, 2023 | 103.00 Mn |
| Jun 30, 2023 | 114.50 Mn |
| Mar 31, 2023 | 40.20 Mn |
| Dec 31, 2022 | 127.60 Mn |
| Sep 30, 2022 | 194.10 Mn |
| Jun 30, 2022 | 111.10 Mn |
| Mar 31, 2022 | 87.60 Mn |
| Dec 31, 2021 | 274.40 Mn |
| Sep 30, 2021 | 184.40 Mn |
| Jun 30, 2021 | 653.90 Mn |
| Mar 31, 2021 | 137.80 Mn |
| Dec 31, 2020 | 75.40 Mn |
| Sep 30, 2020 | 156.20 Mn |
| Jun 30, 2020 | 21.60 Mn |
| Mar 31, 2020 | 44.00 Mn |
| Dec 31, 2019 | 97.80 Mn |
| Sep 30, 2019 | 98.90 Mn |
| Jun 30, 2019 | 31.60 Mn |
| Mar 31, 2019 | 85.00 Mn |
| Dec 31, 2018 | -144.20 Mn |
| Sep 30, 2018 | 41.20 Mn |
| Jun 30, 2018 | 104.70 Mn |
| Mar 31, 2018 | 107.40 Mn |
| Dec 31, 2017 | 381.25 Mn |
| Sep 30, 2017 | 177.29 Mn |
| Jun 30, 2017 | 138.11 Mn |
| Mar 31, 2017 | 183.36 Mn |
| Dec 31, 2016 | 88.42 Mn |
| Sep 30, 2016 | 101.08 Mn |
| Jun 30, 2016 | 96.04 Mn |
| Mar 31, 2016 | 148.77 Mn |
| Dec 31, 2015 | 72.30 Mn |
| Sep 30, 2015 | 182.89 Mn |
| Jun 30, 2015 | 133.35 Mn |
| Mar 31, 2015 | 200.50 Mn |
| Dec 31, 2014 | 111.11 Mn |
| Sep 30, 2014 | 98.45 Mn |
| Jun 30, 2014 | 112.45 Mn |
| Mar 31, 2014 | 112.58 Mn |
| Dec 31, 2013 | 94.99 Mn |
| Sep 30, 2013 | 84.38 Mn |
| Jun 30, 2013 | 60.32 Mn |
| Mar 31, 2013 | 42.96 Mn |
| Dec 31, 2012 | -335.80 Mn |
| Dec 31, 2011 | -615,000.00 |
| Sep 30, 2011 | 562,000.00 |
| Jun 30, 2011 | -863,000.00 |
| Mar 31, 2011 | -216,000.00 |